No Picture
News

Alzheimer’s Association Statement on Lecanemab Phase 3 Full Results

CHICAGO, Nov. 29, 2022 /PRNewswire/ — The Alzheimer’s Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global Phase 3 clinical trial of lecanemab. The data presented today and published in the New England Journal of… Click here to view original post… […]

No Picture
News

Eisai’s expanded Alzheimer’s data leave open questions about safety and clinical benefit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night. In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical… Click here to view original post… […]

No Picture
News

ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE

TOKYO and CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the results from… Click here to view original post… […]

No Picture
News

EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE

TOKYO and CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the results from… Click here to view original post… […]